Correlation Between Summit Therapeutics and 456837AH6

Can any of the company-specific risk be diversified away by investing in both Summit Therapeutics and 456837AH6 at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Summit Therapeutics and 456837AH6 into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Summit Therapeutics PLC and ING GROEP N, you can compare the effects of market volatilities on Summit Therapeutics and 456837AH6 and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Summit Therapeutics with a short position of 456837AH6. Check out your portfolio center. Please also check ongoing floating volatility patterns of Summit Therapeutics and 456837AH6.

Diversification Opportunities for Summit Therapeutics and 456837AH6

0.35

Correlation Coefficient

Summit Therapeutics  456837AH6

Weak diversification

The 3 months correlation between Summit and 456837AH6 is 0.35. Overlapping area represents the amount of risk that can be diversified away by holding Summit Therapeutics PLC and ING GROEP N in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on ING GROEP N and Summit Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Summit Therapeutics PLC are associated (or correlated) with 456837AH6. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of ING GROEP N has no effect on the direction of Summit Therapeutics i.e., Summit Therapeutics and 456837AH6 go up and down completely randomly.

Pair Corralation between Summit Therapeutics and 456837AH6

Given the investment horizon of 90 days Summit Therapeutics PLC is expected to generate 12.99 times more return on investment than 456837AH6. However, Summit Therapeutics is 12.99 times more volatile than ING GROEP N. It trades about 0.09 of its potential returns per unit of risk. ING GROEP N is currently generating about -0.1 per unit of risk. If you would invest  1,946  in Summit Therapeutics PLC on October 24, 2024 and sell it today you would earn a total of  404.00  from holding Summit Therapeutics PLC or generate 20.76% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	70.0%
Values	Daily Returns

Summit Therapeutics PLC  vs.  ING GROEP N

Summit Therapeutics PLC

Risk-Adjusted Performance

6 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Summit Therapeutics PLC are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak primary indicators, Summit Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point.

ING GROEP N

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days ING GROEP N has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, 456837AH6 is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Pair Trading with Summit Therapeutics and 456837AH6

The main advantage of trading using opposite Summit Therapeutics and 456837AH6 positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Summit Therapeutics position performs unexpectedly, 456837AH6 can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in 456837AH6 will offset losses from the drop in 456837AH6's long position.

The idea behind Summit Therapeutics PLC and ING GROEP N pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.